Use: Labeled indications
- Epinephrine injection, USP auto-injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Epinephrine injection, USP auto-injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Epinephrine injection, USP auto-injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.
Anaphylactic reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema. Epinephrine injection, USP auto-injectors are intended for immediate administration as emergency supportive therapy only and are not a substitute for immediate medical care.
Epinephrine injection, USP auto-injector is a non-selective alpha and beta-adrenergic receptor agonist indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis. (1)
Contraindications
4 CONTRAINDICATIONS None None (4)
US FDA labelDosing: Adult
Patients greater than or equal to 30 kg (66 lbs): epinephrine injection, USP auto-injector, 0.3 mg (2) Patients 15 to 30 kg (33 lbs to 66 lbs): epinephrine injection, USP auto-injector, 0.15 mg (2) Inject intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Each device is a single-dose injection.
(2)
2.1 Recommended Dosage According to Patient Body Weight
2.1 Recommended Dosage According to Patient Body Weight Patients greater than or equal to 30 kg (approximately 66 pounds or more): epinephrine injection, USP auto-injector, 0.3 mg Patients 15 kg to 30 kg (33 pounds to 66 pounds): epinephrine injection, USP auto-injector, 0.15 mg
2.2 Administration Instructions
2.2 Administration Instructions Inject the single-dose epinephrine injection, USP auto-injector intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Do not inject intravenously, and do not inject into buttocks, into digits, hands or feet [see Warnings and Precautions (5.2)].
Instruct caregivers of young children who are prescribed an epinephrine injection, USP auto-injector and who may be uncooperative and kick or move during an injection to hold the leg firmly in place and limit movement prior to and during an injection [see Warnings and Precautions (5.2)]. Each epinephrine injection, USP auto-injector is a single-dose epinephrine injection for single use.
Since the doses of epinephrine delivered from epinephrine injection, USP auto-injector are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary. With severe persistent anaphylaxis, repeat injections with an additional epinephrine injection, USP auto-injector may be necessary.
More than two sequential doses of epinephrine should only be administered under direct medical supervision [see Warnings and Precautions (5.1)]. The epinephrine solution in the clear window of the additional epinephrine injection, USP auto-injector should be inspected visually for particulate matter and discoloration. Discarding After Use: The epinephrine injection, USP contains 2 mL epinephrine solution.
Approximately 1.7 mL remains in the auto-injector after activation, but is not available for future use, and should be discarded.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Epinephrine injection, USP auto-injector may be administered to pediatric patients at a dosage appropriate to body weight [see Dosage and Administration (2.1)]. Clinical experience with the use of epinephrine suggests that the adverse reactions seen in children are similar in nature and extent to those both expected and reported in adults. Since the doses of epinephrine delivered from epinephrine injection, USP auto-injectors are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies for the treatment of anaphylaxis have not been performed in subjects aged 65 and over to determine whether they respond differently from younger subjects. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine.
Therefore, epinephrine injection, USP auto-injector should be administered with caution in elderly individuals, who may be at greater risk for developing adverse reactions after epinephrine administration [see Warnings and Precautions (5.5), Overdosage (10)].
Administration
2.2 Administration Instructions Inject the single-dose epinephrine injection, USP auto-injector intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Do not inject intravenously, and do not inject into buttocks, into digits, hands or feet [see Warnings and Precautions (5.2) ]. Instruct caregivers of young children who are prescribed an epinephrine injection, USP auto-injector and who may be uncooperative and kick or move during an injection to hold the leg firmly in place and limit movement prior to and during an injection [see Warnings and Precautions (5.2) ] . Each epinephrine injection, USP auto-injector is a single-dose epinephrine injection for single use. Since the doses of epinephrine delivered from epinephrine injection, USP auto-injector are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary. With severe persistent anaphylaxis, repeat injections with an additional epinephrine injection, USP auto-injector may be necessary. More than two sequential doses of epinephrine should only be administered under direct medical supervision [see Warnings and Precautions (5.1) ] . The epinephrine solution in the clear window of the additional epinephrine injection, USP auto-injector should be inspected visually for particulate matter and discoloration. Discarding After Use: The epinephrine injection, USP contains 2 mL epinephrine solution. Approximately 1.7 mL remains in the auto-injector after activation, but is not available for future use, and should be discarded .
US FDA labelDosage forms
Philippines
- Solution for injection: 1 mg/mL
Registered products in the Philippines
29 products registered with the Food and Drug Administration (FDA) Philippines list Epinephrine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products29
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AccephrineEpinephrine | 1mg/mL Solution for Injection (IM/SC/IV)Type I Clear Glass Ampoule in 1 mL (net content) (Box of 10's) | Rx | Jeil Pharmaceutical Co. Ltd.Republic of Korea | Accesspoint International Trading Inc. | DRP-7828 | Apr 16, 2028 | |
AdlineEpinephrine | 1 mg/mL Solution for Injection (IM/SC/IV Infusion)USP Type I Amber Glass Ampoule x 1 mL (Box of 10's) | Rx | Pt. Phapros TBK.Indonesia | Phoenix Pharmaceutical, Inc.Importer: Bellus Life Solutions, Inc. | DRP-8896-01 | Jun 24, 2031 | |
AdreninEpinephrine (as hydrochloride) | 1 mg/mL (0.1% w/v) Solution for injection (IM/IV/SC)Amber Glass Ampoule x 1 mL (Box of 100's) | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | Phil Pharmawealth Inc.Trader: Oboi Laboratories | DR-XY20374-B | Jul 11, 2028 | |
AdrepineEpinephrine | 1 mg/mL Solution for Injection (IM/IV/SC)Type I amber glass ampule x 1mL in plastic tray x 10's (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-16604 | May 15, 2030 | |
AmiphrineEpinephrine | 1 mg/mL Solution for Injection (I.M./S.C./I.V.)USP Type I amber glass ampoule x 1 mL (net content) (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-10782-05 | Nov 18, 2026 | |
BelphrineEpinephrine | 1 mg/mL Solution for Injection (I.M./S.C./I.V. Infusion)USP Type I amber glass ampoule x 1 ml (Box of 10's) | Rx | Pt. Phapros TbkIndonesia | Cv Clearvue Pharma, Inc.Importer: Bellus Life Solutions, Inc. | DRP-8896 | Jun 9, 2031 | |
EferinEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (I.M./S.C./I.V.)Amber-Colored, Type I Glass Ampoule x 1 mL (Box of 100's) | Rx | Jinling Pharmaceutical Co., Ltd. Zhejiang Tianfeng Pharmaceutical FactoryChina | Global Pharmatrade | DR-XY44890 | Nov 13, 2031 | |
EphedrixEpinephrine | 1 mg/mL Solution for Injection (IM/SC/IV)USP Type I Amber Glass Ampoule x 1 mL (Box of 50's) | Rx | Dai Han Pharm. Co., Ltd.Republic of Korea | Endure Medical Inc. | DR-XY44698 | Jul 2, 2030 | |
EpibbasEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (IM/SC)USP Type I Amber Glass Ampoule x 1 mL (Box of 10's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Raquel-Abbas Pharmaceutical & General Merchandise | DRP-9321 | Mar 5, 2028 | |
EpicareEpinephrine | 1 mg/ml Solution for Injection (I.M./S.C./I.V.)USP Type I amber glass ampoule x 1 mL (net content). Box of 10's. | Rx | Furen Pharmaceutical Group Co., Ltd.China | Euro-Care Products Philippines | DRP-10782 | Nov 18, 2026 | |
EpifedEpinephrine | 1 mg/mL Solution for Injection (I.M./S.C./I.V.)USP Type I amber glass ampoule x 1 mL (net content) (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Federal Pharmaceuticals Inc.Importer: Euro-Care Products Philippines | DRP-10782-03 | Nov 18, 2026 | |
EpikhrizEpinephrine | 1 mg/mL Solution for Injection (I.M./S.C.)USP Type I Amber Glass Ampoule x 1 mL (Box of 10's) | Rx | Merit Organics Ltd.India | Khriz Pharma Trading Inc. | DR-XY49166 | Aug 15, 2029 | |
EPIMEDSEPINEPHRINE | 1 MG/ML SOLUTION FOR INJECTION (I.M./S.C./I.V.)USP TYPE I AMBER GLASS AMPOULE X 1 ML (NET CONTENT) BOX OF 10'S | Rx | FUREN PHARMACEUTICAL GROUP CO., LTD.China | APPLIED PHARMACEUTICAL DISTRIBUTION INCImporter: EURO-CARE PRODUCTS PHILIPPINES | DRP-10782-02 | Nov 18, 2031 | |
EpipaEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (I.M./I.V./S.C.)USP Type 1 amber glass ampoule x 1 mL (Box of 10's) | Rx | Grand Pharmaceutical (China) Co., Ltd.China | Aglobal Care, Inc. | DRP-12273 | Jul 7, 2027 | |
EpiradEpinephrine | 1 mg / mL Solution for Injection (I.M./S.C./I.V.)USP Type I amber glass ampoule x 1 mL (net content) (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | HLM Pharmaceutical Inc.Importer: Euro-Care Products Philippines | DRP-10782-04 | Nov 18, 2026 | |
EpisaveEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (I.M./I.V./S.C.)1 mL USP Type I Amber Glass Ampoule (Box of 10's) | Rx | Grand Pharmaceutical (China) Co., Ltd.China | Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc. | DRP-12078-01 | May 17, 2027 | |
EpixEpinephrine (As Hydrochloride) | 1 mg/mL Solution For Injection (I.M./I.V./S.C.)1 mL USP Type I Amber Glass Ampoule (Box of 10's) | Rx | Grand Pharmaceutical (China) Co., Ltd.China | Aglobal Care, Inc. | DR-XY44310 | May 17, 2027 | |
EpixEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (I.M./I.V./S.C.)1 mL USP Type I Amber Glass Ampoule (Box of 10's) | Rx | Grand Pharmaceutical (China) Co., Ltd.China | Aglobal Care, Inc. | DRP-12078 | May 17, 2032 | |
EsphrineEpinephrine | 1 mg / mL Solution for Injection (I.M/I.V/S.C)Type I amber colored glass ampoule x 1 mL (Box of 10's) | Rx | Maxitech Pharma (Pvt) Ltd.Pakistan | JNG Pharma Philippines, Inc.Importer: Accesspoint International Trading Inc. | DRP-13346-01 | Feb 1, 2028 | |
MaxiphrineEpinephrine | 1mg/mL Solution For Injection (IM/IV/SC)Type 1 amber colored glass ampoule x 1 mL (Box of 10's). | Rx | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-13346 | Feb 1, 2028 | |
NoneEpinephrine (as bitartrate) | 1 mg/mL Solution for Injection (IM/IV/SC)Amber glass ampoule x 1 mL (Box of 50's) | Rx | Atlantic Laboratories Corporation Ltd.Thailand | Phil Pharmawealth, Inc. | DR-XY27825 | Jan 10, 2028 | |
NoneEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (IM/SC)USP Type I Amber Glass Ampoule x 1 mL (Box of 10's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9321-01 | Mar 5, 2028 | |
NoneEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (IM/SC/IV)Type I colorless glass ampoule with blue dot x 1 mL Box of 10's | Rx | Grand Pharmaceutical (China) Co., Ltd.China | First Global Trading Corporation | DR-XY42299 | Jul 29, 2028 | |
PenniphrineEpinephrine | 1 mg / mL Solution for Injection (I.M./I.V./S.C.)Type I amber colored glass ampoule x 1 mL (Box of 10's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Neo Care Philippines, Inc.Importer: Accesspoint International Trading Inc. | DRP-13346-03 | Feb 1, 2028 | |
Q-PixEpinephrine | 1 mg/mL Solution for Injection (I.M./S.C./I.V.)USP Type I amber glass ampoule x 1 mL (net content) (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Quad-Gen PharmaceuticalsImporter: Euro-Care Products Philippines | DRP-10782-01 | Nov 18, 2026 | |
RexiphrineEpinephrine | 1 mg/mL Solution for InjectionType I amber colored glass ampoule x 1 mL (Box of 10's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-13346-02 | Feb 1, 2028 | |
SavephrineEpinephrine (as hydrochloride) | 1 mg/mL Solution for Injection (I.M./I.V./S.C.)1 mL USP Type I Amber Glass Ampoule (Box of 10's) | Rx | Grand Pharmaceutical (China) Co., Ltd.China | Curasave PharmaImporter: Aglobal Care, Inc. | DRP-12078-02 | May 17, 2027 | |
UnbrandedEpinephrine (as hydrochloride) | 1 mg/mL (0.1% w/v) Solution for Injection (IM/IV/SC)Amber Glass Ampoule x 1 mL (Box of 100's) | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | Phil Pharmawealth Inc.Trader: Oboi Laboratories | DR-XY20374 | Sep 25, 2030 | |
UnbrandedEpinephrine | 1 mg/mL Solution for Injection (IM/SC/IV)Amber Glass Ampoule x 1 mL (Box of 100’s) | Rx | Hizon Laboratories, Inc.Rizal | — | DR-4469 | Oct 29, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 0.3 mg (0.3 mg/0.3 mL), clear and colorless solution in single-dose pre-filled auto-injector Injection: 0.15 mg (0.15 mg/0.3 mL), clear and colorless solution in single-dose pre-filled auto-injector Injection: 0.3 mg (0.3 mg/0.3 mL) single-dose pre-filled auto-injector (3) Injection: 0.15 mg (0.15 mg/0.3 mL) single-dose pre-filled auto-injector (3)
Warnings/Precautions
- In conjunction with use, seek immediate medical or hospital care. (5.1)
- Do not inject intravenously, into buttock, or into digits, hands, or feet. (5.2)
- To minimize the risk of injection related injury, hold the child’s leg firmly in place and limit movement prior to and during injection when administering to young children. (5.2)
- Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection. (5.3)
- The presence of a sulfite in this product should not deter use. (5.4)
- Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias. (5.5)
5.1 Emergency Treatment
5.1 Emergency Treatment Epinephrine injection, USP auto-injectors are intended for immediate administration as emergency supportive therapy and are not intended as a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision [see Indications and Usage (1), Dosage and Administration (2) and Patient Counseling Information (17)].
5.2 Injection-Related Complications
5.2 Injection-Related Complications Epinephrine injection, USP auto-injector should only be injected into the anterolateral aspect of the thigh [see Dosage and Administration (2) and Patient Counseling Information (17)]. Do not inject intravenously Large doses or accidental intravenous injection of epinephrine may result in cerebral hemorrhage due to sharp rise in blood pressure.
Rapidly acting vasodilators can counteract the marked pressor effects of epinephrine if there is such inadvertent administration. Do not inject into buttock Injection into the buttock may not provide effective treatment of anaphylaxis. Advise the patient to go immediately to the nearest emergency room for further treatment of anaphylaxis.
Additionally, injection into the buttock has been associated with Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk. Do not inject into digits, hands or feet Since epinephrine is a strong vasoconstrictor, accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area.
Advise the patient to go immediately to the nearest emergency room and to inform the healthcare provider in the emergency room of the location of the accidental injection. Treatment of such inadvertent administration should consist of vasodilation, in addition to further appropriate treatment of anaphylaxis [see Adverse Reactions (6)].
Hold leg firmly during injection Lacerations, bent needles, and embedded needles have been reported when epinephrine injection, USP auto-injector has been injected into the thigh of young children who are uncooperative and kick or move during an injection. To minimize the risk of injection related injury when administering, hold the child’s leg firmly in place and limit movement prior to and during injection.
5.3 Serious Infections at the Injection Site
5.3 Serious Infections at the Injection Site Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Clostridium spores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection.
While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill Clostridium spores. To decrease the risk of Clostridium infection, do not inject epinephrine injection, USP auto-injector into the buttock [see Warnings and Precautions (5.2)]. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site.
5.4 Allergic Reactions Associated with Sulfite
5.4 Allergic Reactions Associated with Sulfite The presence of a sulfite in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations even if the patient is sulfite-sensitive. Epinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though this product contains sodium metabisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons.
The alternatives to using epinephrine in a life-threatening situation may not be satisfactory.
5.5 Disease Interactions
5.5 Disease Interactions Some patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, it should be recognized that the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, patients with these conditions, and/or any other person who might be in a position to administer epinephrine injection, USP auto-injector to a patient experiencing anaphylaxis should be carefully instructed in regard to the circumstances under which epinephrine should be used.
Patients with Heart Disease Epinephrine should be administered with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias [see Drug Interactions (7) and Adverse Reactions (6)].
Other Patients and Diseases Epinephrine should be administered with caution to patients with hyperthyroidism, diabetes, elderly individuals, and pregnant women. Patients with Parkinson’s disease may notice a temporary worsening of symptoms.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Cardiac Glycosides, Diuretics, and Anti-arrhythmics Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.5)]. Antidepressants, Monoamine Oxidase Inhibitors, Levothyroxine, and Antihistamines The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine.
Beta-Adrenergic Blockers The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol. Alpha-Adrenergic Blockers The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha- adrenergic blocking drugs, such as phentolamine.
Ergot Alkaloids Ergot alkaloids may also reverse the pressor effects of epinephrine. Cardiac glycosides or diuretics: observe for development of cardiac arrhythmias. (7) Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines: potentiate effects of epinephrine. (7) Beta-adrenergic blocking drugs antagonize cardiostimulating and bronchodilating effects of epinephrine.
(7) Alpha-adrenergic blocking drugs antagonize vasoconstricting and hypertensive effects of epinephrine. (7) Ergot alkaloids may reverse the pressor effects of epinephrine. (7)
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS Due to the lack of randomized, controlled clinical trials of epinephrine for the treatment of anaphylaxis, the true incidence of adverse reactions associated with the systemic use of epinephrine is difficult to determine. Adverse reactions reported in observational trials, case reports, and studies are listed below.
Common adverse reactions to systemically administered epinephrine include anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; nausea and vomiting; headache; and/or respiratory difficulties. These symptoms occur in some persons receiving therapeutic doses of epinephrine, but are more likely to occur in patients with hypertension or hyperthyroidism [see Warnings and Precautions (5.5)].
Cardiovascular Reactions Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or those receiving certain drugs [see Warnings and Precautions (5.5) and Drug Interactions (7)]. Rapid rises in blood pressure have produced cerebral hemorrhage, particularly in elderly patients with cardiovascular disease [see Warnings and Precautions (5.5)].
Angina may occur in patients with coronary artery disease [see Warnings and Precautions (5.5)]. Rare cases of stress cardiomyopathy have been reported in patients treated with epinephrine. Reactions from Accidental Injection and/or Improper Technique Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area [see Warnings and Precautions (5.2)].
Adverse reactions experienced as a result of accidental injections may include increased heart rate, local reactions including injection site pallor, coldness and hypoesthesia or injury at the injection site resulting in bruising, bleeding, discoloration, erythema or skeletal injury. Lacerations, bent needles, and embedded needles have been reported when epinephrine injection, USP auto-injector has been injected into the thigh of young children who are uncooperative and kick or move during the injection [see Warning and Precautions (5.2)].
Injection into the buttock has resulted in cases of gas gangrene [see Warnings and Precautions (5.2)]. Skin and Soft Tissue Infections Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported following epinephrine injection, including epinephrine injection, USP auto-injector, in the thigh [see Warnings and Precautions (5.3)].
Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties. (6) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no adequate and well controlled studies of the acute effect of epinephrine in pregnant women. In animal reproductive studies, epinephrine administered by the subcutaneous route to rabbits, mice, and hamsters during the period of organogenesis was teratogenic at doses 7 times and higher than the maximum recommended human intramuscular and subcutaneous dose on a mg/m 2 basis.
Epinephrine is the first-line medication of choice for the treatment of anaphylaxis during pregnancy in humans. Epinephrine should be used for treatment of anaphylaxis during pregnancy in the same manner as it is used in non-pregnant patients. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Disease-associated maternal and embryo/fetal risk During pregnancy, anaphylaxis can be catastrophic and can lead to hypoxic-ischemic encephalopathy and permanent central nervous system damage or death in the mother and, more commonly, in the fetus or neonate. The prevalence of anaphylaxis occurring during pregnancy is reported to be approximately 3 cases per 100,000 deliveries.
Management of anaphylaxis during pregnancy is similar to management in the general population. Epinephrine is the first line-medication of choice for treatment of anaphylaxis; it should be used in the same manner in pregnant and non-pregnant patients. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care.
Data Animal Data In an embryofetal development study with rabbits dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including gastroschisis and embryonic lethality) at doses approximately 40 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days). In an embryofetal development study with mice dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including embryonic lethality) at doses approximately 8 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days).
These effects were not seen in mice at approximately 4 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). In an embryofetal development study with hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine was shown to be teratogenic at doses approximately 7 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day).
Mechanism of action
12.1 Mechanism of Action Epinephrine acts on both alpha- and beta-adrenergic receptors.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis.
Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder. When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
Pharmacokinetics
Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.
Pharmacokinetics (US label) US FDA label
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Epinephrine acts on both alpha- and beta-adrenergic receptors. 12.2 Pharmacodynamics Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis.
Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder. When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Epinephrine 1 mg/mL, 1 mL Ampule | ₱2.89–₱38.00Reference ₱21.91 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Epinephrine (adrenaline) |
| PNF listing | Inj.: 1 mg/mL, 1 mL ampul (IV, IM, SC) (as hydrochloride)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 0.3 mg auto-injector (IM-Preload), 0.3 mL preloaded injection penRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Epinephrine · Sportpharm LLC [US FDA-approved label, version 1, October 12, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8e98483-9404-43bc-8800-b827c63c5134
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

